Nature Communications (Aug 2023)

MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia

  • Nicholas T. Crump,
  • Alastair L. Smith,
  • Laura Godfrey,
  • Ana M. Dopico-Fernandez,
  • Nicholas Denny,
  • Joe R. Harman,
  • Joseph C. Hamley,
  • Nicole E. Jackson,
  • Catherine Chahrour,
  • Simone Riva,
  • Siobhan Rice,
  • Jaehoon Kim,
  • Venkatesha Basrur,
  • Damian Fermin,
  • Kojo Elenitoba-Johnson,
  • Robert G. Roeder,
  • C. David Allis,
  • Irene Roberts,
  • Anindita Roy,
  • Huimin Geng,
  • James O. J. Davies,
  • Thomas A. Milne

DOI
https://doi.org/10.1038/s41467-023-40981-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Aberrant enhancer activation is a key mechanism driving oncogene expression in many cancers. While much is known about the regulation of larger chromosome domains in eukaryotes, the details of enhancer-promoter interactions remain poorly understood. Recent work suggests co-activators like BRD4 and Mediator have little impact on enhancer-promoter interactions. In leukemias controlled by the MLL-AF4 fusion protein, we use the ultra-high resolution technique Micro-Capture-C (MCC) to show that MLL-AF4 binding promotes broad, high-density regions of enhancer-promoter interactions at a subset of key targets. These enhancers are enriched for transcription elongation factors like PAF1C and FACT, and the loss of these factors abolishes enhancer-promoter contact. This work not only provides an additional model for how MLL-AF4 is able to drive high levels of transcription at key genes in leukemia but also suggests a more general model linking enhancer-promoter crosstalk and transcription elongation.